Protagonist Therapeutics (PTGX) Net Margin (2017 - 2026)
Protagonist Therapeutics (PTGX) reported Net Margin of 6.71% for Q1 2026, up 4786.0% on a YoY basis from 0.14% in Q1 2025, and up 101.12% sequentially from 596.8% in Q4 2025.
Protagonist Therapeutics (PTGX) Net Margin (2017 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 10 years of Net Margin data on file, last reported at 6.71% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 4786.0% year-over-year to 6.71%; the trailing twelve-month figure through Mar 2026 stood at 154.92% (down 18270.0% YoY), and the FY2025 full-year result was 282.83%, down 34617.0% from the prior year.
- Net Margin improved to 6.71% in Q1 2026, from 596.8% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 87.83% in Q4 2023 to a low of 4966.12% in Q2 2022.
- A 5-year average of 709.63% and a median of 428.53% in 2022 frame the typical range for Net Margin.
- Peak annual rise in Net Margin reached 12750 bps in 2022, while the deepest fall reached 360445 bps in 2022.
- Tracing PTGX's Net Margin over 5 years: stood at 4966.12% in 2022, then jumped by 102 bps to 87.83% in 2023, then retreated by 9 bps to 79.77% in 2024, then slumped by 848 bps to 596.8% in 2025, then surged by 101 bps to 6.71% in 2026.
- Business Quant data shows PTGX's Net Margin at 6.71% in Q1 2026, 596.8% in Q4 2025, and 834.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | 6.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.71% |
| Dec 31, 2025 | -596.80% |
| Sep 30, 2025 | -834.87% |
| Jun 30, 2025 | -627.46% |
| Mar 31, 2025 | -41.15% |
| Dec 31, 2024 | 79.77% |
| Sep 30, 2024 | -710.37% |
| Jun 30, 2024 | -734.15% |
| Mar 31, 2024 | 81.33% |
| Dec 31, 2023 | 87.83% |
| Jun 30, 2022 | -4,966.12% |
| Mar 31, 2022 | -260.26% |
| Dec 31, 2021 | -428.30% |
| Sep 30, 2021 | -328.64% |
| Jun 30, 2021 | -1,361.68% |
| Mar 31, 2021 | -387.75% |
| Dec 31, 2020 | -334.27% |
| Sep 30, 2020 | -59.20% |
| Jun 30, 2020 | -311.92% |
| Mar 31, 2020 | -550.59% |